Clinical bottom line
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has emerged as a promising therapeutic option for patients with diabetic kidney disease (DKD). Recent clinical trials demonstrate that finerenone can significantly reduce the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Its favorable safety profile, particularly regarding hyperkalemia, makes it a viable addition to current treatment regimens, especially for patients who are already on optimized renin-angiotensin-aldosterone system (RAAS) blockade.
What the evidence shows
The pivotal FIDELIO-DKD trial, a randomized controlled trial published in 2020, evaluated the efficacy of finerenone in patients with DKD. The study found that finerenone significantly reduced the risk of kidney failure, a sustained decrease in estimated glomerular filtration rate (eGFR), and renal death by 18% compared to placebo [PMID: 32966714]. Additionally, the trial reported a 14% reduction in the risk of cardiovascular events, including myocardial infarction, stroke, and heart failure hospitalization.
Further supporting evidence comes from the FIGARO-DKD trial, published in 2021, which focused on cardiovascular outcomes. This trial demonstrated that finerenone reduced the risk of cardiovascular events by 13% in a similar patient population [PMID: 34140324]. Both trials highlighted the drug's ability to provide renal and cardiovascular benefits without significantly increasing the risk of hyperkalemia compared to placebo.
Caveats and uncertainty
Despite the promising results, several caveats and uncertainties remain. The long-term effects of finerenone on hard renal endpoints, such as end-stage kidney disease, require further investigation. Additionally, while the incidence of hyperkalemia was relatively low, it remains a concern, particularly in patients with advanced CKD or those on concurrent RAAS inhibitors. Clinicians should monitor serum potassium levels regularly and adjust treatment as necessary.
The trials predominantly included patients with type 2 diabetes and established kidney disease, limiting the generalizability of the findings to other populations, such as those with type 1 diabetes or earlier stages of CKD. Further research is needed to explore the efficacy and safety of finerenone in these groups.
How this may change practice
The introduction of finerenone provides nephrologists with a novel therapeutic option for managing DKD, particularly in patients who have maximized RAAS blockade therapy. Its dual renal and cardiovascular protective effects make it an attractive option for comprehensive risk reduction in this high-risk population. Clinicians should consider incorporating finerenone into treatment regimens for eligible patients, while carefully monitoring for potential adverse effects, particularly hyperkalemia.
The availability of finerenone may also prompt a reevaluation of current treatment guidelines for DKD, potentially leading to its inclusion as a standard therapy alongside RAAS inhibitors. As more data becomes available, particularly regarding long-term outcomes and broader patient populations, the role of finerenone in DKD management is likely to expand.